News

Telaprevir Ups Response Rates Across IL28B Genotypes in Hepatitis C


 

FROM THE ANNUAL DIGESTIVE DISEASE WEEK

Further research, including studies on nonwhites, is needed to confirm these findings, Dr. Jacobson said.

Dr. Jacobson disclosed numerous financial relationships with industry including grant support and other financial benefits from Tibotec and Vertex Pharmaceuticals, which are developing telaprevir together. Several coauthors also disclosed financial relationships including employment with Vertex.

Pages

Recommended Reading

Studies Highlight Role of Primary Care in HIV-Positive Population
MDedge Internal Medicine
C. difficile Increases IBD Patients' Deaths Sixfold
MDedge Internal Medicine
Antibiotics Found to Lower S. Aureus Risk in Acne Patients
MDedge Internal Medicine
FDA May See Advantages for Telaprevir Over Boceprevir
MDedge Internal Medicine
Increasing Disease Activity Means More Infections in RA
MDedge Internal Medicine
FDA Panel Backs Approval of Boceprevir for Chronic Hepatitis C
MDedge Internal Medicine
FDA: Second Protease Inhibitor Backed for Treating Hepatitis C
MDedge Internal Medicine
FDA Targets Unapproved STD Meds Sold Online
MDedge Internal Medicine
Uptake of Meningococcal Vaccine: Awareness Is Not Enough
MDedge Internal Medicine
FDA Clears Quick Test Distinguishing MRSA From MSSA
MDedge Internal Medicine

Related Articles